796 results on '"Iwasa, S."'
Search Results
2. Association Between Nonadherence and Transient Hyperuricemia in Pediatric Kidney Transplantation
3. Association Between Nonadherence and Transient Hyperuricemia in Pediatric Kidney Transplantation
4. 401P A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
5. 143P Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
6. Reversible Optical Effects in Amorphous Semiconductors
7. 473P A phase I study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients with advanced solid tumors including colorectal cancer (CRC)
8. 980P Phase Ib study of a liposomal formulation of eribulin (E7389-LF) + nivolumab (Nivo) in patients (pts) with advanced solid tumors
9. O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma
10. SO-10 Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
11. P-23 Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study
12. 128P Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090
13. Development of a novel redox flow battery for electricity storage system
14. 5-FU INDUCED ENCEPHALOPATHY DURING 5-FU CONTAINING REGIMEN FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA
15. 534MO First in human study of ONO-4578, a PGE2-receptor EP4 antagonist, in monotherapy and combination with PD-1 checkpoint inhibitor nivolumab in patients with advanced or metastatic solid tumours
16. 583P Effect of infusion rate, premedication, and prophylactic peg-filgrastim treatment on the safety of the liposomal formulation of eribulin (E7389-LF): Results from the expansion part of a phase I study
17. 1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
18. O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
19. 17O A first-in-human phase I study of MORAb-202 in patients with folate receptor alpha-positive advanced solid tumors
20. P1016Novel surgical ablation technique using ultrasonic scalpel for atrial fibrillation in mitral valve surgery
21. Phase I study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumours: Primary results of dose-escalation part
22. Contribution of metabolic status to the development of urinary tract stone which required surgical intervention
23. A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE study
24. TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study
25. A novel electrode material for electric double-layer capacitors
26. Efficient production of a functional mouse/human chimeric Fab′ against human urokinase-type plasminogen activator by Bacillus brevis
27. Revision of the cytological diagnosis of CNS relapse into aseptic meningitis in a patient with TEL-AML1+ acute lymphoblastic leukaemia by FISH analysis of mononuclear cells in cerebrospinal fluid
28. Efficient production of anti-(hepatitis B virus) antibodies and their neutralizing activity in chimpanzees
29. Glycosaminoglycans in neonatal urine
30. Identification of serum microRNAs predicting the response to nivolumab in patients with advanced gastric cancer
31. A phase I trial of the safety and pharmacokinetics of cemiplimab, a human monoclonal antibody to programmed death-1, in Japanese patients with advanced malignancies, including expansion cohorts for patients with non-small-cell lung cancer
32. Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial
33. CT image features of peritoneal metastasis and outcomes of the advanced gastric cancer patients receiving second-line chemotherapy
34. Color Selection and Editing for Palette-Based Photo Recoloring
35. Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial
36. Phase I study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors
37. A study of the Ce(III)/Ce(IV) redox couple for redox flow battery application
38. c-Abl expression in oral squamous cell carcinomas
39. Impact by age on dose-limiting toxicities in phase 1 oncology trials of cytotoxic agents and molecular targeted agents
40. Comparison of model-based dose escalation design with rule-based design of phase I oncology trials
41. Effect of digested slurry on the dry matter production and arbuscular mycorrhizal colonization of two genotypes of Zoysia grass
42. Evaluation of the safety and efficacy of combined the CART and chemotherapy for gastrointestinal cancers with massive ascites
43. Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT)
44. Prognostic factors of patients received immunocheckpoint inhibitors in oncology phase 1 trials
45. 1764P - A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE study
46. 526PD - TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study
47. 348P - Phase I study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumours: Primary results of dose-escalation part
48. P128 - Contribution of metabolic status to the development of urinary tract stone which required surgical intervention
49. A phase 1 study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies
50. J-FORCE study: A randomized, double-blind, placebo-controlled phase III study evaluating olanzapine (5 mg) combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based, highly emetogenic chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.